- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
ASH Annual Meeting | Conferences
Clinical Efficacy Observed With BCMA-Directed ADC MEDI2228 in Triple-Refractory Myeloma
December 09, 2020
MEDI2228 demonstrated promising clinical efficacy as treatment of patients with relapsed/refractory multiple myeloma with triple-refractory disease experiencing maintained responses in a phase 1 study.
Early-Phase Study Shows Activity and Safety for TRPH-222 in R/R NHL
December 09, 2020
A phase 1 trial showed early signals of tolerability and efficacy in patients with relapsed or refractory B-cell non-Hodgkin lymphoma with TRPH-222 across dose levels.
Higher CPX-351 Induction Doses Lead to Delayed Hematologic Recovery in AML
December 08, 2020
Treatment with higher doses of CPX-351 in younger patients with newly diagnosed high-risk or secondary acute myeloid leukemia was significantly associated with prolonged hematologic recovery times during induction cycles 1 and 2.
Results of Selinexor Added to Pd Regimen Moves Myeloma Study on to Phase 3
December 08, 2020
The combination of selinexor plus pomalidomide and low-dose dexamethasone led to favorable responses in a cohort of patients with heavily pretreated multiple myeloma, warranting further investigation of the regimen in a phase 3 trial.
Brentuximab Vedotin Tolerable With High Response Rates in Older Patients with cHL
December 08, 2020
In older patients with comorbid classical Hodgkin lymphoma who are deemed unfit for combination chemotherapy, treatment with the antibody dug conjugate brentuximab vedotin appeared tolerable and achieved high response rates that were durable in some patients, according to results from the phase 2 SGN35-015 study.
REACH3 Study Demonstrates Promising Objective Responses in Chronic GVHD
December 08, 2020
Robert Zeiser, MD, discusses the findings from the phase 3 REACH3 clinical trial of ruxolitinib as treatment of patients with chronic graft-versus-host disease with an inadequate response to corticosteroids.
MPN Driver Mutations Can Be Acquired as Early as in Utero, Study Shows
December 08, 2020
A study presented during the 2020 ASH Annual Meeting has suggested that certain driver mutations for myeloproliferative neoplasms can be traced back to when they were acquired as early as in utero.
Acalabrutinib Demonstrates Low Cardiac Risk in Chronic Lymphocytic Leukemia
December 08, 2020
In a pooled analysis of 4 clinical trials in chronic lymphocytic leukemia, patients who received treated with acalabrutinib monotherapy had a low incidence of cardiac toxicities leading to treatment discontinuation, according to a presentation given during the American Society of Hematology Annual Meeting.
Significant Responses Seen With Investigational BTK Inhibitor in Pretreated CLL/SLL Population
December 08, 2020
A high objective response rate was observed in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma treated with LOXO-305, according to results of the phase 1/2 BRUIN trial presented during the 2020 ASH Annual Meeting.
Mosunetuzumab Elicits High and Durable Responses in Subgroups of Patients With FL
December 08, 2020
A phase clinical trial has demonstrated that administering a mosunetuzumab fixed-duration leads to high, durable, and consistent responses in patients with follicular lymphoma across multiple subgroups. Data from the study were presented during the virtual 2020 American Society of Hematology Annual Meeting.